USPTO serial 79189100
FLUOROPASSIV
Reviewed by CopyMark Law Group
Reg. 5135131Status 709
- Filing date
- Status date
- Registration date
- Feb 7, 2017
- Examiner
- VAGHANI, MAYUR C
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with FLUOROPASSIV?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Renfrewshire PA4 9RR, GB
Renfrewshire PA4 9RR, GB
Renfrewshire PA4 9RR, GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
JEFFREY H. GREGER
JEFFREY H. GREGER ROBERTSMLOTKOWSKISAFRANCOLE&CALDERONPC7918 JONES BRANCH DRIVE, SUITE 500MCLEAN, VA 22102UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 010 | Surgical apparatus and instruments; medical apparatus and instruments for use in cardiovascular procedures; prosthetic vascular grafts; prosthetic endovascular grafts; stents, vascular prostheses; vascular prostheses with flared outflow; vascular prostheses with customisable outflow; prosthetic vascular woven grafts; prosthetic endovascular knitted grafts; expanded polytetrafluoroethylene (ePTFE) vascular grafts; surgical implants comprising prosthetic materials; suture materials; patches for repair and reconstruction of internal tissue, namely, cardiovascular patches, pericardial patches, and carotid patches, namely, surgical mesh comprised primarily of prosthetic materials; implantable medical systems, namely, cardiac valves for surgical prostheses, stents, prosthetic vascular grafts, vascular prostheses, prosthetic vascular grafts, prosthetic endovascular grafts, and catheters; implantable medical devices, namely, implants consisting of prosthetic materials, synthetic vascular prostheses, prosthetic vascular grafts, and synthetic heart valve conduits; prosthetic vascular grafts; prosthetic endovascular grafts; surgical graft materials, namely, prosthetic vascular grafts, and vascular prostheses for the treatment of aneurysmal or occlusive arterial disease; medical devices for use in endovascular procedures, namely, medical devices for use in treating cardiovascular disease; synthetic thoracic stents; synthetic thoracic stent grafts; synthetic stent grafts; synthetic stent graft systems comprised of synthetic stent grafts, stent delivery systems, and stent graft delivery systems; stent graft systems comprising more than one component comprised of synthetic stent grafts, stent delivery systems, and stent graft delivery systems; stent graft systems comprising components of more than one stent graft comprised of synthetic stent grafts, stent delivery systems, and stent graft delivery systems; stent graft systems comprising components of more than one type of stent graft comprised of synthetic stent grafts, stent delivery systems, and stent graft delivery systems; thoracic stent graft systems comprised of synthetic stent grafts, stent delivery systems, and stent graft delivery systems; prosthetic systemic vascular grafts; prosthetic vascular straight grafts; prosthetic vascular abdominal grafts; prosthetic vascular thoracic grafts; prosthetic vascular branched grafts; prosthetic vascular pre-curved grafts; prosthetic vascular aortic arch grafts; prosthetic vascular branched arch grafts; delivery systems for synthetic stent graft systems comprised of medical instruments for intraluminal emplacement of stents or of synthetic stent grafts, namely, stent or synthetic stent graft delivery systems; aneurysm repair systems comprised of catheter delivered stent grafts, medical instruments for intraluminal emplacement of stents or stent systems or of synthetic stent grafts, namely, stent delivery systems or stent graft delivery systems or synthetic stent graft delivery systems; medical devices, namely, aneurysm repair devices; cardiac valves for surgical prostheses; cardiac valve replacement systems, namely, prosthetic cardiac valves; heart valves, namely, prosthetic heart valves; heart valve conduits, namely, catheters for implanting heart valves; cardiac patches, namely, cardiovascular patches, pericardial patches, and carotid patches, namely, surgical mesh comprised primarily of prosthetic materials; vascular patches, namely, cardiovascular patches, pericardial patches, and carotid patches, surgical mesh comprised primarily of prosthetic materials; thin wall cardiovascular patches, namely, surgical mesh comprised primarily of prosthetic materials; thin wall carotid patches, namely, surgical mesh comprised primarily of prosthetic materials; fluoropolymer cardiovascular patches, namely, surgical mesh comprised primarily of prosthetic materials; fluoropolymer carotid patches, namely, surgical mesh comprised primarily of prosthetic materials; knitted cardiovascular patches, namely, surgical mesh comprised primarily of prosthetic materials; knitted carotid patches, namely, surgical mesh comprised primarily of prosthetic materials; gelatin sealed cardiovascular patches, namely, surgical mesh comprised primarily of prosthetic materials; gelatin sealed carotid patches, namely, surgical mesh comprised primarily of prosthetic materials; parts and fittings for all of the aforementioned goods | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 21, 2024 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Apr 30, 2024 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Apr 30, 2024 | INPC | INVALIDATION PROCESSED | — |
| Apr 18, 2024 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Aug 18, 2023 | C71T | CANCELLED SECTION 71 | — |
| Feb 7, 2022 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jun 24, 2017 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 3, 2017 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jun 3, 2017 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 7, 2017 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Feb 7, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 22, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 22, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 2, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 17, 2016 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Oct 13, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 22, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 22, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 17, 2016 | ALIE | ASSIGNED TO LIE | — |
| Sep 8, 2016 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 8, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 5, 2016 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 20, 2016 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 20, 2016 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 20, 2016 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jul 19, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 19, 2016 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 15, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 15, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 14, 2016 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |